普灵生物医药

Puling Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the discovery and development of next-generation antibody-drug conjugates (ADCs) for oncology. The company leverages its proprietary PL-Linker platform, which is designed to enhance the stability and homogeneity of ADCs, thereby improving their therapeutic index and safety profile. Its lead candidate, PL001, is a HER2-targeting ADC currently in clinical development for various solid tumors. Puling Biopharma aims to address significant unmet medical needs in cancer treatment by optimizing the synergy between potent payloads and site-specific conjugation technologies.